Oxaliplatin
Product Images NDC 79672-825

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oxaliplatin (NDC 79672-825). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nextgen Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Oxaliplatin 01

Chemical structure of Oxaliplatin showing the central platinum (Pt) atom coordinated to a cyclohexane-1,2-diamine (NH2 groups attached) and two oxalate groups (C and O atoms forming carboxylate groups).*

FDA Label Image

Oxaliplatin 02

A Kaplan-Meier survival curve graph depicting disease-free survival (DFS) probability over 72 months for two treatment arms, FOLFOX4 and LV5FU2. The solid line represents FOLFOX4 and the dashed line LV5FU2. The graph includes the number and percentage of events, hazard ratio with confidence interval, p-value from a stratified logrank test, and counts of patients at risk over time.*

FDA Label Image

Oxaliplatin 03

A Kaplan-Meier survival curve showing Disease-Free Survival (DFS) probability over months up to approximately 72 months. Two treatment arms are compared: FOLFOX4 versus LV5FU2, both followed by DUKES C. The graph includes a hazard ratio (0.78) with 95% confidence interval (0.65 to 0.93) and a logrank test p-value of 0.005, indicating statistical comparison results for stage III patients.*

FDA Label Image

Oxaliplatin 04

A Kaplan-Meier survival curve chart showing the percentage of patients surviving over 24 months for three treatment groups: Oxaliplatin Injection USP plus 5-FU/LV, Oxaliplatin Injection USP plus irinotecan, and Irinotecan plus 5-FU/LV. The chart includes median survival times for each group, with Oxaliplatin plus 5-FU/LV at 19.4 months, Oxaliplatin plus irinotecan at 17.6 months, and Irinotecan plus 5-FU/LV at 14.6 months. A p-value of less than 0.0001 is indicated for the comparison between Oxaliplatin plus 5-FU/LV and irinotecan plus 5-FU/LV.*

FDA Label Image

Oxaliplatin 05

Label for Oxaliplatin For Injection, USP, distributed by Nextgen Pharmaceuticals LLC. The label shows a strength of 50 mg per vial, with instructions for intravenous use. It states the vial contains oxaliplatin USP 50 mg, inactive lactose monohydrate 450 mg, and specifies it is a sterile lyophilized powder for single use only. Storage conditions and handling instructions are also noted.*

FDA Label Image

Oxaliplatin 06

Packaging label for Oxaliplatin 50 mg/vial injection by Nextgen Pharmaceuticals LLC. The label states it is for injection, USP grade, single-use vial, cytotoxic agent, preservative-free, and for intravenous use only. The label includes storage instructions, barcode placement, and manufacturer details. The vial strength and usage instructions are clearly shown.*

FDA Label Image

Oxaliplatin 07

Oxaliplatin For Injection, USP 100 mg per vial, sterile lyophilized powder for intravenous use, distributed by Nextgen Pharmaceuticals LLC. The label includes storage instructions, ingredients including lactose monohydrate, and a barcode. The product is a single-use vial and preservative free.*

FDA Label Image

Oxaliplatin 08

Packaging label for Oxaliplatin For Injection, USP by Nextgen Pharmaceuticals LLC. The label indicates a dosage strength of 100 mg per vial, a single-use vial format, and specifies the product as a cytotoxic agent for intravenous use only. The label includes storage instructions, warnings against reconstitution with sodium chloride, and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.